SLDB - Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

2024-06-25 09:00:00 ET

Summary

• Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval.
• Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candidates in their pipeline. Thus, Elevidys's monopoly could be under a threat.
• Based on my technology assessment, only two product candidates have the potential to disrupt Elevidys monopoly in the next two to three years.
• Thus, I consider that CTLT’s and SRPT’s revenue driven by Elevidys is not only safe, but poised to grow given the label expansion in the U.S.

Thesis

Catalent (CTLT), who is partially responsible for manufacturing Elevidys on behalf of Sarepta, observed its shares gaining approximately 3% last Friday given the recent FDA approval of Elevidys label expansion.

In a recent article , I discussed the upside potential of Elevidys, a single-shot gene therapy aimed for the treatment of Duchenne’s muscular dystrophy ((DMD)), developed by Sarepta Therapeutics, Inc. (SRPT). As a consequence of Elevidys’ label expansion, Sarepta’s share price surged from $123.50 to $160.70, and temporarily reached $173.25, which is currently the all-time-high for the stock....

For further details see: